Single versus dual EGFR/PARP inhibition: Mechanistic rationale, synthetic approaches, pharmacophoric features,...

Area of Science:

• Medicinal Chemistry
• Oncology
• Drug Discovery

Background:

• Cancer therapy necessitates novel targeted drugs due to the limitations of current treatments.
• Simultaneous inhibition of EGFR and PARP is a promising strategy, exploiting the link between cancer signaling and DNA repair.
• Existing reviews focus on individual inhibitors, leaving a gap in medicinal chemistry perspectives on dual-action agents.

Purpose of the Study:

• To provide a focused medicinal chemistry review on dual EGFR/PARP inhibitors.
• To highlight rational design strategies for achieving balanced dual-target inhibition.
• To summarize advancements in multifunctional anticancer agents.

Main Methods:

• Review of pharmacophore fusion, linker engineering, and scaffold optimization for dual inhibitors.
• Analysis of structure-activity relationships (SAR) for dual-target potency and selectivity.
• Discussion of synthetic strategies and computational studies (molecular docking) for hybrid molecules.

Main Results:

• Identified key scaffolds (quinazoline, quinoline, pyrimidine, nicotinamide) for dual EGFR/PARP inhibitor design.
• Detailed molecular determinants influencing dual-target activity and selectivity.
• Summarized emerging multifunctional systems with combined EGFR inhibition, PARP suppression, and DNA-damaging effects.

Conclusions:

• Dual EGFR/PARP inhibitors represent a rational approach to advanced cancer therapy.
• Medicinal chemistry strategies are crucial for optimizing balanced inhibition and selectivity.
• Multifunctional agents integrating multiple therapeutic modalities show future promise.